Edition:
United Kingdom

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

125.55GBp
18 Jan 2019
Change (% chg)

1.00 (+0.80%)
Prev Close
124.55
Open
124.40
Day's High
128.75
Day's Low
123.20
Volume
2,074,315
Avg. Vol
3,968,697
52-wk High
504.60
52-wk Low
75.48

Select another date:

Tue, Dec 18 2018

Indivior plans cheaper opioid addiction drug if rivals launch copycats

Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug.

UPDATE 3-Indivior plans cheaper opioid addiction drug if rivals launch copycats

* Shares jump 17 pct after strategy update (Recasts lead, updates shares)

Indivior to launch cheaper opioid addiction drug; maintains forecast

Dec 18 British drugmaker Indivior Plc said on Tuesday it would launch a cheaper version of its blockbuster opioid addiction treatment drug, while maintaining its full-year profit and revenue forecast.

Indivior wins fresh hold on Dr. Reddy's Suboxone copy

Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday.

REFILE-UPDATE 1-Indivior wins fresh hold on Dr. Reddy's Suboxone copy

Dec 12 Indivior Plc has secured another hold on the launch of a generic competitor to its best-selling opioid addiction drug in the United States, the London-listed company said on Wednesday.

Indivior says wins fresh hold on Suboxone copy

Dec 12 Indivior Plc said on Wednesday a U.S. court ruling had put a hold on Indian rival Dr. Reddy's Laboratories launching a generic competitor to the London-listed drugmaker's bestselling opioid addiction treatment.

Indivior to discuss strategy, contingency plans on Dec. 18

Nov 27 Indivior Plc said it will discuss its strategy and contingency plans in a conference call on Dec. 18, after an U.S. court allowed rival Dr. Reddy's Laboratories Ltd to sell a copycat version of its blockbuster drug Suboxone.

Indivior backs FY view, warns of generic rival hit; shares fall

Shares of drugmaker Indivior Plc fell as much as 10 percent on Wednesday, a day after the company lost a legal battle that will allow an Indian generic rival to sell a copycat version of its blockbuster film-based opioid addiction treatment.

UPDATE 1-Indivior backs FY view, warns of generic rival hit; shares fall

Nov 21 Shares of drugmaker Indivior Plc fell as much as 10 percent on Wednesday, a day after the company lost a legal battle that will allow an Indian generic rival to sell a copycat version of its blockbuster film-based opioid addiction treatment.

Indivior sticks to FY outlook, warns of hit from generic rival

Nov 21 British drugmaker Indivior Plc stuck to its full-year forecast on Wednesday even after a U.S. court allowed an Indian generic rival to sell a copycat version of Indvior's blockbuster opioid addiction treatment drug.

Select another date: